In June ----, the World Bank announced that it has approved USD---mn in additional funding to help improve Bangladesh s health system. This brings the total support from the World Bank on health projects to USD---mn. ...This brings the total support from the World Bank on health projects to USD---mn. The support is expected to help the government sustain and improve immunisation coverage, improve deliveries for pregnant women at public facilities and tackle multi-drug resistant tuberculosis. In July ----, Bangladesh s Export Promotion Bureau noted that the country exported USD--mn of medicines for the fiscal year -------. ...In August ----, the High Court in Bangladesh ordered -- drugmakers to stop manufacturing medicines following revelations that the firms had ignored a ban imposed in June. Under the original order, -- were told to cease manufacturing and firms will now have till August -- ---- to stop producing the products.
...In Q--- Bangladesh s Risk/Reward Index (RRI) score remains unchanged from last quarter at --.- out of ---. Bangladesh also retains its ranking position in BMI s RRI matrix, standing as the --th most attractive market to pharmaceutical investors out of -- markets in the Asia Pacific region. ...In Q--- Bangladesh s Risk/Reward Index (RRI) score remains unchanged from last quarter at --.- out of ---. Bangladesh also retains its ranking position in BMI s RRI matrix, standing as the --th most attractive market to pharmaceutical investors out of -- markets in the Asia Pacific region. Bangladesh s score is driven by a large pharmaceutical market (market expenditure score of --.- out of --) and rapid drug market expansion (sector value growth score of -.- out of --), but dragged down by low levels of drug spending per capita (spending per capita score of -.- out of --) and limited intellectual property protection (patent respect score of -.- out of -). ...Bangladesh also retains its ranking position in BMI s RRI matrix, standing as the --th most attractive market to pharmaceutical investors out of -- markets in the Asia Pacific region. Bangladesh s score is driven by a large pharmaceutical market (market expenditure score of --.- out of --) and rapid drug market expansion (sector value growth score of -.- out of --), but dragged down by low levels of drug spending per capita (spending per capita score of -.- out of --) and limited intellectual property protection (patent respect score of -.- out of -).
...Many domestic manufacturers lack full-spectrum generic drug manufacturing capabilities. Prices are kept low, with the government reluctant to approve price increases, despite changes in currency fluctuations and the rising cost of raw materials. ...